The decision to downsize the company was not taken lightly, as CloudWhale Intelligence has always prided itself on being a people-first organization. Zhang explained that the move was necessary in order to align the company's workforce with its evolving business needs and strategic priorities. By identifying redundancies and optimizing resources, CloudWhale Intelligence aims to create a leaner and more focused team that can better adapt to the rapidly changing market landscape.In recent years, the gaming industry has seen a significant increase in the number of female players. Recognizing this trend, Lenovo, a leading technology company, has released an official guide to help female gamers improve their gaming experience. The guide focuses on the proper usage of keyboards, which are essential tools for playing games effectively.Word count: 470
Heartbroken Married At First Sight UK star reveals shock split after five months and reveals reason it didn’t work outIn terms of display, the GPD WIN4 boasts a high-resolution screen that delivers vibrant colors and sharp details. Whether you're exploring vast open worlds or engaging in fast-paced multiplayer battles, the display of the GPD WIN4 ensures an immersive gaming experience like never before. The touchscreen functionality adds an extra layer of convenience, allowing for intuitive navigation and interaction with games and apps.
In addition to the seasonal factors at play, other key drivers will also impact the future trajectory of pork prices. Factors such as feed costs, disease outbreaks, government policies, and international trade dynamics will all play a role in shaping the market outlook. For example, rising feed costs could put pressure on producers' margins, potentially leading to lower production levels and higher prices. On the other hand, increased government support for the swine industry or changes in trade policies could have a positive impact on prices.
Macy's Inc. M revealed the findings of its investigation into a significant accounting mishap that impacted its financial reporting over several years. The inquiry determined that a single employee's repeated errors and subsequent coverup led to $151 million in falsely recorded expenses, The Wall Street Journal reports . What Happened: The discrepancies, which stemmed from understated small package delivery expenses starting in late 2021, were perpetuated by intentional erroneous entries and falsified documentation. This manipulation concealed the true costs until its discovery in the fall of 2024. While Macy's terminated the employee responsible, the company stated the individual did not gain financially from the misconduct, WSJ reports. Also Read: Alphabet’s Quantum Willow Chip Wows Analyst: Google At The ‘Leading Edge Of Technology Innovation’ Why It Matters: The timing of the investigation and its fallout couldn't be more critical, given the holiday shopping season's importance to retail. With net sales declining by 2.4% to $4.7 billion for the recent quarter, the company is striving to rebuild investor trust and refocus on operational improvements. On Wednesday, the company announced adjusted earnings per share for the third quarter that still managed to beat expectations despite the scandal, coming in at $0.04 versus a consensus of $0.03. Macy's highlighted sales strength at its first 50 locations, Bloomingdale's and Bluemercury, partially offsetting broader declines. According to The Journal, CEO Tony Spring emphasized the need to "strengthen existing controls" to prevent future errors of this magnitude . Macy's also announced plans to close 65 stores this year, surpassing its initial estimate of 55, and raised $66 million through asset sales during the quarter. Despite these measures, activist investors continue to pressure the retailer to unlock more value, including considering a real estate spinoff. Read Next: Magnificent Seven Tech Titans Hit $18.2 Trillion Market Cap: Alphabet, Amazon, Apple, Meta, Tesla Jointly Notch All-Time Highs Photo: Shutterstock This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Title: Female Gamers Complain About the Difficulty of Pressing "W+Spacebar" on Keyboards: Lenovo Offers Online TutorialAnd now, the baton has been passed to the second Chinese player set to make his mark against Atletico Madrid, carrying the hopes and aspirations of a nation eager to see their footballing talents shine on the global stage. The excitement surrounding this upcoming match is palpable, with fans eagerly awaiting the opportunity to witness history being made once again.
None
Footy legend Paul 'Fatty' Vautin confirms his next move after shock departure from Channel 9 Paul Vautin announced retirement from Channel 9 Says he will never work another day in his life Details the moment he wanted out of the NRL By JAMES COONEY FOR DAILY MAIL AUSTRALIA Published: 22:43 GMT, 3 December 2024 | Updated: 22:43 GMT, 3 December 2024 e-mail 11 shares View comments NRL funny man Paul Vautin has revealed that he will never work another day in his life after announcing his retirement and bringing to an end a 33-year broadcasting career with Channel 9. Footy fans hoped the larrikin commentator would continue doing other media work following his shock announcement , but the NRL icon has now ruled it out. 'I will never work again. I am done. I'm not looking for work,' the Manly great told SEN radio on Tuesday. 'I don't want to do anything. Not radio, not podcasts. I don't want to do anything. I'm happy.' Vautin, who lives on the Gold Coast , says he's very happy just spending time at home relaxing. 'I can spend a whole day on my own and be happy with myself,' he said. Footy legend Paul Vautin says that he will never work another day in his life Vautin says he won't do radio, podcasts or any other kind of media 'Sometimes I read, go for a walk or mow the grass. I'm very happy in my own company.' Vautin was the face of the popular sports talk show The Footy Show for the better part of 24 years before he was unceremoniously dismissed in 2017 after ratings dwindled. He revealed the exact moment he knew it was time to walk away from his job. 'Something changed this year. I'd be driving up in three hours of traffic on a Friday afternoon going 'oh my god what am I doing?' he said. 'In the end I just felt as though I'd rather be at home watching the footy on a Friday night than working on it. 'I still love the game immensely but I just thought 'you know what I think I'm done'. 'There was one particular moment when the Brisbane Broncos were playing the Roosters on a Friday night at Suncorp and look it was a pretty good game, I was commentating with Joey and we were having a good time. 'Then 20 minutes into the second half I was looking out at the field going, 'Oh my god I am so bored'. Vautin, who played 204 games for Manly and represented his state and country in rugby league, described his time in TV as an absolute privilege 'I drove home thinking wow that had never happened before and I knew then it was the beginning of the end.' Vautin told SMH that it was a privilege to work with so many talented people throughout his career at Channel 9. 'I still love Nine, and all the great people there, and I still love the game, I really do – it gave me everything,' he said. 'I can't believe how fortunate I've been to play the game at the level I did. I thought when I came to Sydney I'd have a few years in reserve grade and then probably go home. Instead, I got to play with some of the greats of the game who I now get to call friends. 'And then to think that I somehow had a career in media that went for as long as it did. I'm just so grateful for all the people and my family who have helped me along the way.' NRL Share or comment on this article: Footy legend Paul 'Fatty' Vautin confirms his next move after shock departure from Channel 9 e-mail 11 shares Add commentPower Management System Market | Business Growth, Development Factors, Current and Future Trends till 2031 | Seekway Technology Ltd. SeeReal Technologies GmbH Sony Corporation
The fact that 36 senior officials have been investigated within the first half of this year sends a strong message that no one, regardless of rank or position, is immune from accountability. The CCDI's swift and decisive actions demonstrate the government's determination to uphold clean governance and maintain the integrity of the Communist Party.Qatar committed to global efforts to boost resilience to drought: Dr Subaie
In the recent years, Sudan has been making headlines for its political turmoil and upheaval. One of the prominent figures in this tumultuous period is the former President Omar al-Bashir, who ruled the country for three decades before being ousted in a military coup in 2019. Stock market today: Losses for Big Tech pull US indexes lower
In conclusion, the European Union's investigation into Google over alleged secret ad dealings with Meta underscores the growing scrutiny of tech giants' business practices and the need for greater transparency and fairness in the digital advertising market. The outcome of the probe will be closely watched by industry players and regulators, as it has the potential to reshape the competitive dynamics of the online advertising industry and set a precedent for enforcing antitrust regulations in the digital age.
Interestingly, the report also revealed that former Manchester United player Darren Fletcher has been considered for a more prominent role in the club's recruitment structure. Fletcher, who currently serves as a technical director at the club, could potentially take on additional responsibilities in the absence of a traditional Director of Football.(Bloomberg) -- Human plasma is a protein-rich compound made by spinning blood so fast that the heavier red blood cells are flung aside like clothes on the side of a washing machine, leaving behind a straw-colored liquid. It is also the basis of CSL Ltd.’s $88 billion health-care empire. Australia’s largest biotechnology company delivered a 750% return for investors in the decade before the onset of the Covid-19 pandemic by dominating the global market for the critical substance. However, since the start of 2020, the stock has plateaued for the longest period since its listing. The firm first had difficulty getting people to both sell and gather blood from which to make plasma during lockdowns and then struggled with its largest-ever acquisition. Chief Executive Paul McKenzie, who is a year and a half in the job, needs to find a way to boost profits from CSL’s 2022 purchase of Switzerland-based Vifor to revive the shares. The $11.7 billion acquisition was designed to diversify the company’s portfolio by adding treatments for iron deficiency and kidney disease. However, generic competition in the European Union has eroded margins for Vifor’s best-selling medication and slashed returns on invested capital, convincing some investors that CSL overpaid for the business. Still, the acquisition has catapulted CSL into the position of the world’s largest provider of iron therapies. One in four people globally don’t have enough of the mineral, which is essential to transport oxygen in the blood and make muscles work. Demand for iron supplements will help boost the unit’s sales over the next five years, according to McKenzie. In particular, he expects iron infusions to provide plenty of opportunities for growth by treating various ailments. “There are so many things that iron could benefit,” said McKenzie in an interview in Melbourne. “Heart failure we believe is a big one. Anemia is a big one. Women’s health is a big one.” He has yet to convince the market. Since the deal closed in August 2022, the company’s shares have dropped 5.5% compared with a 20% gain for the broader ASX200 index, weighed down by disappointment in the Vifor acquisition. CSL “absolutely paid too much,” said Jun Bei Liu, a portfolio manager at Tribeca Investment Partners. “In time, they will generate a return. It’s just they should have done their due diligence a bit better. For such a large acquisition, investors put a lot of faith in the management.” She said the purchase made strategic sense. The company’s move into iron supplements was spurred in part by a growing need for the treatments. The World Health Organization estimates that in 2021, anemia affected roughly 2 billion people, with the vast majority of cases attributed to iron deficiency. Children and women of reproductive age suffer at the highest rates. That same year, the WHO began urging hospitals to screen for anemia and optimize iron levels in patients ahead of planned surgeries, aiming to reduce the reliance on higher-risk blood transfusions. A study published this month highlighted the growing importance of this approach, finding that a single intravenous iron treatment reduces hospitalization risk by 17% for anemic heart failure patients. Plasma is still the company’s biggest business, accounting for about 72% of sales and 66% of profit. It is ubiquitous in hospitals’ operating rooms globally and is used for bleeding disorders and burns. Plasma is also the basis for immunoglobulin, which is used to treat autoimmune diseases, such as Stiff Person Syndrome, which affects Canadian-born singer Celine Dion. With almost 350 plasma collection centers in the US, Europe and China, CSL is one of the world’s largest and most efficient producers of the material. The company is also the world’s second-largest maker of flu vaccines. Its success in plasma stems from a series of acquisitions orchestrated by former CEO and current chairman Brian McNamee. Over the course of a 23-year career, he snapped up rivals including businesses founded by Switzerland’s Red Cross and German Nobel laureate Emil von Behring, the father of serum therapy. CSL traces its roots to 1916, when the Australian government set up Commonwealth Serum Laboratories in response to World War I cutting off the country’s access to life-saving medicines from overseas. It was listed in 1994 as part of a wave of initial public offerings of state-owned companies that included Qantas Airways Ltd., Telstra Group Ltd. and the Commonwealth Bank of Australia. “There was a lot of skepticism for an ex-government group, that it would be very fat and very lazy,” said Michael Glenane, who was an analyst for McIntosh Securities, the lead manager on the CSL listing. “At that stage there was very limited understanding of what the actual company did.” Some forward-looking investors could see CSL was “a cash machine because of high depreciation charges and pretty lucrative government contracts,” said Glenane. That turned it into a favorite for both retail and institutional investors. Australia’s A$4 trillion ($2.6 trillion) pension industry poured into the stock with some of the largest funds among the top 10 owners. So did small individual investors, drawn to CSL’s capital appreciation. “It has an incredibly loyal retail shareholder base,” said Michael Muntisov, who has monitored the company for five years for the Australian Shareholders Association, which represents thousands of individual investors. “And you see that at the AGM, when it can sometimes resemble a love fest.” The love was lacking this year. At the company’s AGM in October, frustrated with the company’s performance more than 26% of shareholders opposed the pay package for top management. Under Australia’s corporate governance rules, this is termed a “first strike”. This is important because if a quarter or more of shareholders vote against executives’ pay the following year, it will trigger a subsequent vote on whether the board should be dissolved. “We will go back and look in detail and say, ‘look, are there further things that we can modify that would satisfy people?’” said Chairman McNamee. “But do I ever think we're going to get a hundred percent support for remuneration? No.” Vifor’s top seller is Ferinject, a treatment for anemia that is infused rather than swallowed. Putting iron compounds straight into the bloodstream makes it easier for the body to absorb them. In the EU, Ferinject faces increased competition from generics and has had to cut prices in response. In the US, the company has been hit by what’s known as step edits, a way in which insurers prioritize less expensive medicines. This has held sales below the company’s initial expectations. While the business has not been as profitable as anticipated, CSL defends the acquisition, arguing that the long-term outlook for iron treatments makes it an attractive market to be involved in. “There’s no doubt that we underestimated some of the competitive challenges,’’ said McNamee, citing the competition from generics and US step edits as examples. “But that doesn’t mean the categories in which (Vifor) operates aren’t ones in which we want to compete in.” The company’s specialized treatments for people with kidney disease took a hit from Covid, which has been particularly deadly for people on dialysis. Some studies have suggested that GLP-1 weight-loss drugs, such as Wegovy, could also curb kidney disease. McKenzie said CSL is monitoring the development of those medicines but does not currently see them as a threat. The US is the company’s largest market and CSL does not expect the incoming Trump administration to have a significant impact on its business in the country. Even if vaccine skeptic Robert F. Kennedy Jr. is confirmed as Secretary of Health, the company anticipates continued demand for its products. “At the end of the day, Americans care about people being well and healthy and I really don’t have any significant concern for our life-saving drugs and our life-saving vaccines being impacted,” McNamee said. While CSL’s expansion into iron treatments has not gone to plan, it is still expanding the business. The company recently started selling Ferinject in Canada and has started operations in China. CEO McKenzie calls the market for iron treatments “underserved” and says demand for the element’s medicinal uses will eventually offset Vifor’s lower-than-expected earnings. Some of the company’s long-term investors back his assessment. “CSL has an outstanding track record over the long term,” said David Grace of the Australian Foundation Investment Company, which owns about A$629 million of the company’s shares and has been invested since at least 2005. “We haven’t seen that in Vifor yet, but we’re confident we will.” More stories like this are available on bloomberg.com ©2024 Bloomberg L.P.
LOS ANGELES (AP) — Receiver Demarcus Robinson will not be suspended by the Los Angeles Rams this week after his arrest on suspicion of driving under the influence. Robinson will be available to play when the Rams (5-6) visit the New Orleans Saints on Sunday, Rams coach Sean McVay said Wednesday. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Heartbroken Married At First Sight UK star reveals shock split after five months and reveals reason it didn’t work outLooking ahead, China's trade outlook remains optimistic, supported by the gradual recovery of the global economy and the government's commitment to further opening up its market and promoting international cooperation. As China continues to deepen its economic reforms and strengthen its trade relations with other countries, the country is poised to play an even more significant role in shaping the future of global trade.CrowdStrike reports first full quarter results after causing biggest worldwide tech disruption in history